This is a case report of an 11-year-old boy with attention deficit hyperactivity disorder who developed unusual cardiac repolarisation changes associated with palpitations on treatment with a standard dose of atomoxetine. The unusual cardiac repolarisation changes on the electrocardiogram (ECG) disappeared on stopping the atomoxetine. The importance of ECG monitoring for palpitations associated with atomoxetine and the need for long-term cardiovascular safety studies for atomoxetine in children and adolescents are highlighted.

Atomoxetine is a potent inhibitor of the presynaptic norepinephrine transporters, and is the first non-stimulant drug licensed for the treatment of attention-deficit hyperactivity disorder (ADHD).

Several noradrenergic drugs have been associated with …